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Abstract
Background: To define the NF-kappaB activation in early stages of hepatocarcinogenesis and its
IkappaB's degradation profiles in comparison to sole liver regeneration.
Methods: Western-blot and EMSA analyses were performed for the NF-kappaB activation. The
transcriptional activity of NF-kappaB was determined by RT-PCR of the IkappaB-α mRNA. The
IkappaB's degradation proteins were determined by Western-blot assay.
Results:  We demonstrated the persistent activation of NF-kappaB during early stages of
hepatocarcinogenesis, which reached maximal level 30 min after partial hepatectomy. The DNA
binding and transcriptional activity of NF-kappaB, were sustained during early steps of
hepatocarcinogenesis in comparison to only partial hepatectomy, which displayed a transitory NF-
kappaB activation. In early stages of hepatocarconogenesis, the IkappaB-α degradation turned out
to be acute and transitory, but the low levels of IkappaB-β persisted even 15 days after partial
hepatectomy. Interestingly, IkappaB-β degradation is not induced after sole partial hepatectomy.
Conclusion:  We propose that during liver regeneration, the transitory stimulation of the
transcription factor response, assures blockade of NF-kappaB until recovery of the total mass of
the liver and the persistent NF-kappaB activation in early hepatocarcinogenesis may be due to
IkappaB-β and IkappaB-α degradation, mainly IkappaB-β degradation, which contributes to gene
transcription related to proliferation required for neoplasic progression.
Background
NF-kappaB/Rel family proteins participate in the tran-
scription of several cellular genes, including oncogenes,
cell cycle regulation genes, proteins related to stress, dif-
ferentiation, cytokine and cytokine receptors, all of which
are involved in proliferation and inflammation processes
[1]. The NF-kappaB/Rel protein family includes protonco-
gene c-rel, p50/p105 (NF-kB 1), p52/p100 (NF-kB 2), p65
(Rel A), and Rel B. NF-kappaB which is present in the
cytosol as inactive dimmer associated with the inhibitory
protein IkappaB. When this last one is phosphorylated, it
is broken down by the 26 S proteasome in response to a
wide variety of stimuli such as tumoral necrosis factor
alpha (TNF-α), phorbol myristate acetate (PMA), lipopol-
ysaccharides (LPS), interluekine 1 (IL-1) and others.
Finally, active NF-kappaB is released and translocates to
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the nucleus [1]. The principal isoforms of IkappaB inhib-
itor are IkappaB-α and IkappaB-β, even though three
more proteins exist which are implicated in this process:
IkappaB-γ, IkappaB-ε and Bcl-3 [2,3].
NF-kappaB has recently related to oncogenesis develop-
ment because of its role in cell survival, adhesion, differ-
entiation, apoptosis and cell growth. Many tumor and
transformed cell lines, such as leukemia, lymphoma, mye-
loma, melanoma, prostate, colon, breast, pancreas and
head and neck squamous cell carcinoma, express NF-kap-
paB constitutively [4]. Several varieties of tumor support
the role of NF-kappaB in the oncogenesis process. Among
this evidence, previous reports show the involvement of
the oncogene v-rel, member of the NF-kappaB/Rel family,
which when injected into young chickens, is able to
induce aggressive lymphomas [5]. A process, in which NF-
kappaB plays a critical role in a proliferation program, is
that of hepatic regeneration. After a partial hepatectomy
the remaining liver recovers the total mass of the original
liver [6]. Many factors are involved in the liver regenera-
tion program, such as the activation of post-hepatectomy
factor(s) (PHF)/NF-kappaB, through which hepatocytes
regulate their mitogenic program during liver regenera-
tion [6]. This constitutive activation of NF-kappaB has
been associated with the preferential degradation of
inhibitor IkappaB-β. LPS and IL-1 produce persistent acti-
vation of NF-kB as a result of both IkappaB-α and Ikap-
paB-β degradation, while other inducers, such as TNF-α
and PMA cause a transient induction of NF-kappaB affect-
ing only IkappaB-α. Indeed this constitutive NF-kappaB
activation related to gradual depletion of IkappaB-β, has
been shown in the human T-Cell leukemia virus type 1
Tax [7,8].
However, incomplete knowledge of the molecular mech-
anism involved in persistent NF-kappaB activation in can-
cer development has hindered the use of therapeutic
targets to block the proliferation of transformed cells. On
the other hand, although the activation of nuclear factors
has been studied extensively in well established cancerous
tissue or in transformed cell lines, the mechanisms that
allow the activation of nuclear factors during the initial
stages of carcinogenesis in animal models, is poorly
understood.
Using a modified Resistant Hepatocyte model [9,10] to
induce liver cancer, we demonstrated the persistent NF-
kappaB activation and differential degradation profiles of
IkappaB-α and IkappaB-β when compared to liver regen-
eration. By means of Western-blot, EMSA and RT-PCR
analysis, we demonstrated the persistent activation of NF-
kappaB in the early stages of hepatocarconogenesis, and
this result correlated with the selective degradation of
inhibitors IkappaB-α and IkappaB-β in contrast to the
hepatic regeneration that only manifested transitory NF-
kappaB activation and IkappaB-α degradation.
Results
Translocation induction of NF-kappaB during initial 
hepatocarcinogenesis
We investigated early changes concerning NF-kappaB acti-
vation in the hepatocarcinogenesis model according to
the scheme in figure 1. We tested the Rel A/p65 nuclear
levels, present in different extracts taken from untreated
animals (CN) and from DEN treatment animals, 7 d after
its administration; from animals treated with DEN plus 2-
AAF, sacrificed 24 h after the last dose of 2-AAF; from ani-
mals treated with DEN plus 2-AAF and PH (TC), and
finally from animals with only PH. The last two groups
were examined at 15, 30 and 60 min; 24 and 48 h, and 15
d after PH. Twenty µg of nuclear protein were separated
on 8% SDS-polyacrilamide gel, and inmunoblot analysis
was performed using pAb anti-p65, and normalized using
pAb anti-lamin B (Upstate, NY and Santa Cruz Biotech-
nology Inc., respectively). Densitometric analysis of the
65 kD and lamin B bands in all groups was performed.
Mean ± SD values from three different samples in dupli-
cated observations was performed, where the aP values <
0.05 were considered significant. As shown in figure 2, we
observed an increase in the Rel A/p65 nuclear levels from
7 d after DEN treatment with respect to normal control
(CN). The DEN treatment plus the administration of three
2-AAF doses, sacrificed 24 h after the last 2-AAF dose, fur-
ther incremented the Rel A/p65 nuclear levels. After com-
plete treatment (TC), the nuclear level of Rel A/p65
increased further and reached its maximum level at 30
min after PH. Interestingly, the nuclear level of Rel A/p65
was sustained above control levels at 24 h, and even 15 d
after PH.
Persistent union of Rel A/p65 to DNA in early HC
NF-kappaB binding activity to consensus kappaB site was
analyzed by their DNA union in the EMSA assay. The
nuclear extracts (10 µg) were incubated with {γ-32P} end-
labelled consensus kB oligonucleotide using T4 polynucle-
otide kinase, followed by electrophoresis and analysis by
autoradiography. For the competition assay, the cold kap-
paB site oligo-nucleotide was used. Samples of TC and HP
groups were examined at 30 min and 24 h after PH (Figure
3A). The maximal binding activity of NF-kappaB com-
plexes to DNA in the TC group was found 30 min after PH
in 76% above the control levels (Figure 3B), this results
are in agree with previous reports that shown a similar NF-
kappaB complexes activation behavior [6]. There were dif-
ferences in the amount of the Rel A/p65 binding activity
after carcinogenic treatment, when compared with only
the hepatectomyzed group. The HP group showed the
same trend of maximal binding activity at 30 min, reach-
ing 126% above control levels; however, the TC groupJournal of Carcinogenesis 2007, 6:5 http://www.carcinogenesis.com/content/6/1/5
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maintained the DNA binding activity of 28% above the
levels found in the HP group at 24 h after PH, indicating
a persistent activation of NF-kappaB complexes during the
initial steps of hepatocarcinogenesis in contrast to hepatic
regeneration.
IkappaB-α expression is sustained in early steps of 
hepatocarcinogenesis
After detecting the persistent binding activity of nuclear
NF-kappaB in the initial steps of hepatocarcinogenesis, we
searched for an indication of transcriptional activity car-
ried out by NF-kappaB. Studies indicated that I kappa B
alpha gene is exclusively transcribed by the 65-kilodalton
transactivating subunit of NF-kappaB [11,12], then we
compared the levels of IkappaB-α mRNA by semiquanti-
tative RT-PCR of TC group in contrast to the HP group
(Figure 4A). Total RNA (1 µg) was performed; the ampli-
fication products of the 329 pb, were determined by
means of electrophoresis in 2% agarose gel stained with
ethidium bromide. The densitometric analysis of the Ika-
ppaB-α RNAm bands was quantified and normalized
according to α-actin mRNA and expressed as mean ± SD
aP < 0.05 against control, bP < 0.05 compared 24 h post-
PH in TC against HP group by Student's t test. We
observed an 18% increase in IkappaB-α mRNA levels 30
min after PH in the TC group, (Figure 4B), however, it was
not significant. The sole PH in the HP group after 30 min
produced a higher IkappaB-α expression level of 55%
above levels of non-treated rats. Nevertheless in the TC
group, after 24 h the mRNA levels diminished to a level
only 40% below that of non-treated rats, while after the
sole PH, the transcriptional levels dramatically decreased
to 88.47%, when comparing both groups to that of non-
treated rats (Figure 4B). These latter differences are statis-
Experimental design Figure 1
Experimental design. Five groups of Fisher 344 rats were subjected to different treatments according to a modified Semple-
Roberts hepatocarcinogenesis model. Group 1: CN (n = 3), received no treatment. The second group (n = 3), received 200 
mg/kg of DEN as initiator (ip). Group 3 (n = 3) received the same dose of DEN and on 7 d three daily serial doses of 2-AAF (20 
mg/kg) orally. The fourth group (TC) (n = 18, 3 rats every time of sacrifice), received the DEN (200 mg7kg), the three daily 
serial doses of 2-AAF (20 mg/kg) at 7 d, before partial hepatectomy (PH) on 10 d. The fifth group received only partial hepate-
ctomy (n = 18, 3 rats every time of sacrifice).Journal of Carcinogenesis 2007, 6:5 http://www.carcinogenesis.com/content/6/1/5
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tically significant and strongly suggest that transcriptional
activity of NF-kappaB in early steps of hepatocarcinogen-
esis is increased and sustained at 24 h in contrast to that
observed after PH which showed only a transitory
increase.
Degradation of IkappaB-α and IkappaB-β in early HC 
whereas hepatic regeneration affects only IkappaB-α
Previous studies have indicated that activation of NF-kap-
paB correlates with IkappaB's degradation [13]. Therefore,
we assessed protein levels of IkappaB-α and IkappaB-β
from liver cytosolic extracts in the initial stages of hepato-
carcinogenesis in comparison with liver regeneration. The
IkappaB cytosolic protein level was assayed by means of
Western blotting. Twenty µg of rat liver cytosolic extracts
were separated on 12% SDS-PAGE, and inmunoblot anal-
ysis was performed using the IkappaB-α and IkappaB-β
antibodies. Densitometric analysis of the 35 and 45 kD
bands respectively in all groups was performed. The pro-
tein level of IkappaB-α of the TC group 7 d after DEN
administration or at 10 d, 24 h after the last dose with 2-
AAF, revealed that IkappaB-α levels were not altered (Fig-
ure 5). This situation may be a consequence of a rapid
recovery of the protein levels. On the other hand, on the
same day 10, the IkappaB-α protein was rapidly degraded
15 min after PH, and reached the maximal degradation
level at 30 min post-PH. Interestingly, the decrease of the
IkappaB-α protein continued for up to 24 and 48 h and its
levels were below those of non-treated rats, even 15 d after
PH. Similarly, the 45 kD IkB-β band in the protein of the
TC group was affected but later (60 min) after PH, and its
levels remained low even at 24 and 48 h (Figure 6). This
experiment highlighted differences in the degradation
kinetics between IkappaB-α and IkappaB-β. According to
our results, a similar behavior has been shown in relation
to the NF-kappaB activity, which reaches its maximum
within 30 min and decays rapidly within 4 h to control
levels in 70Z/3 cells stimulated by TNF-α [14]. We
observed that the NF-kappaB activity persisted for over 15
d post-PH in the initial phases of hepatocarcinogenesis,
and IkappaB-α and IkappaB-β decrease displayed similar
behavior. Once the degradation profile of both IkappaB-α
and β was observed in initial steps of hepatocarcinogene-
sis, we determined their degradation profile at 15, 30 and
60 min, 24 and 48 h and 15 d after only PH. The PH treat-
ment caused a loss of IkappaB-α protein which reached its
maximal peak at 30 min post-PH, and was sustained 24 h
after surgery (Figure 5). Degradation of IkappaB-α was
higher in the TC group in comparison to the liver regener-
ation group. There were clear differences between both
groups, at 30 min, 24 and 48 h post-PH. Intriguingly,
there was no effect on IkappaB-β degradation in the post-
PH profile at any time analyzed (Figure 6). These results
suggest the existence of a different mechanism regulating
NF-kappaB activation in the initial stages of chemical
hepatocarcinogenesis, as opposed to liver regeneration,
and as reflected by differential degradation of IkappaB's.
Discussion
The fact that interventions during the first 10 d in the
modified Resistant Hepatocyte Model (RH) [10], which
includes a partial hepatectomy as proliferative stimulus,
are sufficient for inducing liver cancer permit us to study
of the molecular pathways during the progress of neoplas-
tic foci towards malignant cancer [9]. We hereby report
NF-kappaB activation and the degradation profiles of Ika-
ppaB during these initial 10 d of chemical hepatocarcino-
genesis. In this period we find a persistent NF-kappaB
activation response, as compared to activation observed
after PH alone. Our results agree with previous reports
that indicate that NF-kappaB activation persists 25 d and
even 28 d after initiating treatment with modified RH
model, and remains activated even during more advanced
stages or in cancerous liver tissue [10,15]. Some studies
Nuclear translocation of Rel A/p65 during early stages of  hepatocarcinogenesis Figure 2
Nuclear translocation of Rel A/p65 during early 
stages of hepatocarcinogenesis. A: Western blot analysis 
of Rel A/p65. (CN) Normal control, (DEN) diethylnitro-
samine, (2-AAF) 2-acetylaminofluorene, (PH) partial hepatec-
tomy. B: Densitometric analysis of the 65 kD bands. All 
samples were normalized with lamin B. Mean values ± S.D. 
from three different observations. aP < 0.05, aaP < 0.005 
against control, (n = 3) by ANOVA test.Journal of Carcinogenesis 2007, 6:5 http://www.carcinogenesis.com/content/6/1/5
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indicate that NF-kappaB is activated by several carcino-
gens and tumor promoters that include benzo(a)pyrene,
UV radiation and phorbol esthers (PMA) [16,17]. Moreo-
ver, tumor cells have been found to express a continuous
NF-kappaB activation. This has been shown in cells rang-
ing from leukemia, lymphoma, myeloma, and prostate
and breast cancer [5]. We hypothesized a similar persist-
ent NF-kappaB activation in the modified RH model dur-
ing early stages of hepatocarcinogenesis, and therefore
decided to explore NF-kappaB activation after DEN treat-
ment, during promoter administration and further on
after PH. The Rel A/p65 nuclear levels in nucleus was
incremented seven days after DEN administration, and
the maximal level was found at 10 d, 30 min after PH. Pre-
vious reports shown a high increment of NF-kappaB acti-
vation by 30 min post-PH, but decayed drastically after 60
min [6]. However, our results in the TC group showed that
the level of Rel A/p65 displayed a maximal translocation
at 30 min after PH, which was sustained above the basal
levels even after 15 d. It is noteworthy in the TC group that
NF-kappaB/DNA association and the mRNA levels of Ika-
ppaB-α increased at 30 min, and this transcriptional activ-
ity was sustained above the level in hepatectomy after 24
h. After the sole PH the IkappaB-α mRNA levels dimin-
ished beyond basal levels at 24 h, possibly due to auto-
regulatory feedback which blocks the NF-kappaB activa-
tion, through a temporal increment of IkappaB-α synthe-
sis.
IkappaB-α and IkappaB-β respond differently to inducers
of NF-kappaB activity. For instance TNF-α and PMA pro-
duce rapid and transient activation of NF-kappaB which
only affects IkappaB-α complexes, whereas LPS and IL-1
cause persistent activation of NF-kappaB affecting both,
IkappaB-α and β complexes [7]. It seems that in our carci-
nogenic model involving a PH as proliferative stimulus,
NF-kappaB responds differently as compared with a sole
PH. Previous stages in the PH in the modified hepatocar-
cinogenesis model did not cause a diminution of the pro-
tein levels of IkappaB-α; we speculate that this response
was due to the new re-synthesis of IkappaB-α. However,
the profile of IkappaB-α levels was different after PH; in
the TC group it began to decrease at 15 min, the lowest
concentration was reached at 30 min, at it was maintained
even after a further 15 d. In the liver regeneration, we
showed an IkappaB-α decrease of cytosolic protein levels
with a minimum at 30 min as reported elsewhere [6],
whereas, the magnitude of this decrement was greater in
the TC group in comparison to liver regeneration. The
most striking difference after PH in the TC group in com-
parison to that of liver regeneration, was the preferential
degradation of IkappaB-β in early HC, low levels of Ikap-
DNA binding activity of Nuclear Factor-kappaB in hepatocarcinogenesis and liver regeneration Figure 3
DNA binding activity of Nuclear Factor-kappaB in hepatocarcinogenesis and liver regeneration. A: Representa-
tive EMSA assay. B: Densitometric analysis of the NF-kappaB complexes bands in control, hepatocarcinogenesis and liver 
regeneration. A mixture of three different rats from each group was evaluated in a single experiment. Non specific signal (n.s.).Journal of Carcinogenesis 2007, 6:5 http://www.carcinogenesis.com/content/6/1/5
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paB-β appeared from 7 d after DEN administration,
remained low at 24 h after the last dose with 2-AAF, in rats
treated with DEN plus 3 doses of 2-AAF, and reached its
lowest concentration 60 min after PH. In comparison, in
liver regeneration there were no changes in cytosolic pro-
tein levels at any of the time analyzed. From the literature
it is quite clear that IkappaB-β, has a slower degradation
than IkappaB-α, which agrees with our results. Previous
reports have shown that IL-1 induced a slower IkappaB-β
degradation than IkappaB-α in glial cells, accompanied
with a persistent long term activation of NF-kappaB [18].
Furthermore, IkappaB-β has been shown to be a less-effi-
cient substrate for the IkappaB-kinase (IKK) when com-
pared with IkappaB-α, therefore, it has been proposed
that the IkappaB-β has a slower rate of phosphorylation
kinetic [19]. It has been suggested that IkappaB-β phos-
phorylation may be a critical stage in the regulation of
inhibition activity [20,21]. In a hyperphosphorylated
state, IkappaB-β is degrades by means of prior ubiquitina-
tion, but the inhibitory activity is displayed [22,23] in a
phosphorylated form and in the case of hypophosphor-
ylate, the domain of nuclear localization of Rel A/p65 is
not masked, permitting NF-kappaB/IkappaB-β complexes
to enter the nucleus and support the persistent NF-kappaB
activation [24].
Another point of consideration in our study was the Ikap-
paB-α mRNA diminution at 24 h after PH, which is less
pronounced in the hepatocarcinogenesis group in con-
trast to the group which was only hepatectomized. It has
been suggested that upon activation of NF-kappaB, the
newly synthesized IkappaB-α attenuates the NF-kappaB
nuclear translocation, entering the nucleus and displacing
NF-kappaB bound to DNA [11]. In an attempt to explain
this phenomenon, we hypothesized the coexistence of
inactive binary complexes IkappaB-α/NF-kappaB and
active NF-kappaB complexes activation in the nucleus.
Theses studies and our results point a major IkappaB-β
role in persistent NF-kappaB activation. The presence of
the two IkappaB molecules should allow greater flexibility
in the Rel transcription factor regulation, since both
inhibitors respond differentially to proliferating stimuli
[25]. These capacities of IkappaB's have been tested; Ikap-
paB-α is a 10 times more efficient inhibitor of NF-kappaB
than IkappaB-β, a capacity which results from the ability
to remove NF-kappaB from DNA [26]. Possibly, IkappaB-
α corresponds to stress situations, while the NF-kappaB
persistent activation is an obliged response to the chronic
inflammation condition, infection, differentiation and
carcinogenesis. It has been shown that p65/IkappaB-β
complexes are associated with kappaB-Ras proteins [27].
These ternary complexes respond differentially to extracel-
lular signals, due to the incapacity of IKK to phosphor-
ylate IkappaB-β in presence of k-Ras, sice kappaB-Ras
masks the exposed p65 nuclear localization signal (NLS)
[28]. It's important to point out that binary IkappaB-β/
NF-kappaB complexes remain entirely in the cytosol,
although IkappaB-α complexes wait around close to the
nucleus, a difference which may confer more efficient
activity [29]. In order to explain the different inhibition
capacities of IkappaB, a novel computational program has
been developed to predict temporal control to NF-kappaB
activation based on coordinate degradation of both Ikap-
paB. This model indicates a certain responsibility on the
part of IkappaB-α for the negative feedback which leads to
a transitory NF-kappaB activation, while IkappaB-β works
to reduce the oscillatory potential of the system and to sta-
bilize the NF-kappaB response during prolonged stimuli
[30].
Expression of IkappaB-α mRNA in hepatocarconogenesis  and liver regeneration Figure 4
Expression of IkappaB-α mRNA in hepatocarcono-
genesis and liver regeneration. Expression levels of Ikap-
paB-α mRNA in early stages of hepatocarcinogenesis and 
during liver regeneration by semiquantitative RT-PCR. A: 
Representative agarose gels. B: Densitometric analysis of the 
IkappaB-α RNAm bands was quantified and normalized 
according to α-actin mRNA and expressed as mean ± S.D. (n 
= 3) aP < 0.05 against control, bP < 0.05 compared 24 hr 
post-HPx in TC against HP group by Student's t test.Journal of Carcinogenesis 2007, 6:5 http://www.carcinogenesis.com/content/6/1/5
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Conclusion
In summary, our results have identified that NF-kappaB
complexes responds in various ways signalling differences
during early stages in the hepatocarcinogenesis model ver-
sus a sole liver regeneration induced by PH. In the hepa-
tocarcinogenesis model, the IkappaB-α degradation turns
out to be acute and transitory, and IkappaB-β degradation
persists for long periods. After the sole PH, IkappaB-β is
not degraded, only degradation of IkappaB-α is observed,
which is very likely to stimulate transitorily transcription
factors response, and to assure the blockade of NF-kappaB
up until recovering the total mass of the liver. We suggest
that during persistent NF-kappaB activation in the early
stages of hepatocarcinogenesis, the participation of Ikap-
paB-β degradation is important for contributing to the
proliferation of transcription genes needed for neoplastic
proliferation. These results open the possibility that Ikap-
paB-β degradation is caused by alternative activation
pathways other than IkappaB-α signalling in early hepato-
carcinogenesis.
Methods
Animal treatment and experimental groups
Male Fisher rats 344 weighing 180–200 g were housed in
a room at constant temperature. They had free access to
water and laboratory diet food. Forty five animals were
randomly assigned to 5 groups, it is to say, 3 rats in every
time of sacrifice. The control group (CN) received no
treatment (n = 3). The second group received one sole
dose of diethylnitrosamine (DEN) (200 mg/kg) ip as ini-
titator and was sacrificed 7 d after DEN administration (n
= 3). The third group, was treated with one sole dose of
DEN (200 mg/kg) ip and seven days after DEN adminis-
tration, they received three daily oral serial doses of a sus-
pension of 2-acetylaminofluorene (2-AAF) (SIGMA-
ALDRICH Quimica) as promotion stimulus, at dose of 25
mg/kg and were sacrificed 24 h after the last dose of 2-
AAF. The fourth group, the complete treatment group
(TC), received treatment which induces liver cancer
according to a modified version of the Solt and Farber
model [10]. These animals were initiated using DEN (200
mg/kg) ip and on the seven day after DEN administration,
they were promoted with an oral suspension of 2-AAF, at
dose of 25 mg/kg for three consecutives days. On day 10
animals underwent two-thirds partial hepatectomy (PH)
as proliferating stimulus and this group was sacrificed at
different periods at 15, 30 and 60 min; 24, 48 h and 15 d
after partial hepatectomy. The fifth group was treated with
only PH. The animals of this group were sacrificed at dif-
ferent periods after PH, at 15, 30 and 60 min; 24, 48 h and
15 d. Livers were washed in physiological saline solution
and frozen in liquid nitrogen and other sections were fro-
zen in 2-methylbutane to crio-protection and stored at -
79°C. The figure 1 shows the experimental design for each
group, and the times of sacrifice are indicated with this
symbol:  . The 100% of the animals survived up to sac-
rifice time.
Western-blot analysis
For the analysis of Rel A/p65, IkappaB-α and IkappaB-β,
nuclear and cytosolic extracts were prepared from frozen
liver samples [31,32]. Twenty µg of extracts proteins were
separated using 10% SDS-PAGE for p65 and at 12% for
IkappaB-α and β. The separated proteins were transferred
to PVDF membranes. Non-specific binding was blocked
by pre-incubation of the PVDF in 1% non-fat milk (5% w/
v), Tween 20 (0.1% v/v) in phosphate buffered saline
before being incubated overnight at 4°C with polyclonal
anti-p65 (Upstate, NY, USA), anti-IkappaB-α and anti-
IkappaB-β (Santa Cruz Biotechnology, Santa Cruz, CA)
antibodies, in a 3% non-fat milk and 0.05% albumin
bovine (Sigma-Aldrich) Tween 20 in phosphatase-buff-
ered saline. Bound primary antibody was detected using
horseradish peroxidase conjugated anti-rabbit and anti-
mouse antibodies (Santa Cruz Biotechnology, Santa Cruz,
CA) by chemiluminiscence using the Luminol kit (Santa
Cruz Biotechnology, Santa Cruz, CA) and developed in a
photographic plaque (Konica, JP). The samples were nor-
malized using β-actin and lamin B (Santa Cruz Biotech-
nology, Santa Cruz, CA) for cytoplasm and nuclear
extracts respectively. The density of the specific Rel A/p65
(65 kD), IkappaB-α (45 kD) and β (35 kD) bands, was
quantified using an imaging densitometer software (anal-
ysis Imaging System, GmbH).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were incubated with consensus oligonu-
cleotides of kappaB site (5'-AGC TAA GGG ACT TTC CGC
TGG GGA CTT TCC AG-3') (Invitrogen Corp. N.Y.). The
oligonucleotides were labeled with {γ-32P} by T4 polynu-
cleotide kinase for 1 h at 37°C. Binding reactions
included 10 µg of nuclear protein in incubation buffer
(HEPES 120 mmol/L, EDTA 1 mmol/L, glycerol 25%,
MgCl2 8 mmol/L, KCl 60 mmol/L and Tris-HCl 40 mmol/
L), spermidine 10 mmol/L, poly dI:dC 0.5 µg (Invitrogen
Corp. NY) and 50 ng of the oligonucleotide labelled kap-
paB site. The samples were electrophoresed through a 6%
polyacrylamide gel for 2 h at 100 EV. The gel was dried in
a vacuum and autoradiographed at -70°C for 12 h. The
bands were densitometrically analyzed.
Reverse transcription-polymerase chain reaction (RT-
PCR)
The total RNA extraction and electrophoresis gel agarose
were elaborated using standard methods [12,13]. The
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Hepatocarcinogenesis treatment causes acute and sustained degradation of IkappaB-α Figure 5
Hepatocarcinogenesis treatment causes acute and sustained degradation of IkappaB-α. A: Representative West-
ern blotting of the cytosolic degradation of IkappaB-α during early stages of the hepatocarcinogenesis model. B: Densitometric 
analysis of the 35 kD bands. Mean values ± S.D. of three different observations. aP < 0.05, aaP < 0.005 against control, bP = 
0.05, bbP = 0.005 against respectively bar, (n = 3) by ANOVA test.Journal of Carcinogenesis 2007, 6:5 http://www.carcinogenesis.com/content/6/1/5
Page 9 of 11
(page number not for citation purposes)
The liver regeneration not induces the IkappaB-β degradation while the hepatocarcinogenesis treatment causes a persistent  IkappaB-β degradation Figure 6
The liver regeneration not induces the IkappaB-β degradation while the hepatocarcinogenesis treatment 
causes a persistent IkappaB-β degradation. A: Representative Western blotting of the cytosolic degradation of IkappaB-
β. B: Densitometric analysis of the 45 kD bands. Mean values ± S.D. of three different observations. aP < 0.05, aaP < 0.005 
against control, bP = 0.05, bbP = 0.005 against respectively bar, (n = 3) by ANOVA test.Journal of Carcinogenesis 2007, 6:5 http://www.carcinogenesis.com/content/6/1/5
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cDNA synthesis and PCR were performed in one step
(One step RT-PCR System, Gibco Invitrigen Corp. NY). To
the reaction mix were added 0.2 µmol/L of primer for Ika-
ppaB-α gene, and 0.04 µg of total RNA. To verify contam-
ination with DNA, samples were analyzed using PCR
assay. The program cycle consisted of 45 min at 45°C for
cDNA synthesis, 2 min at 94°C followed by 45 s at 94°C
for denaturalization, the annealing time was 45 s at 63°C,
and 15 min at 72°C for final elongation. To find an ade-
quate exponential amplification region to avoid the satu-
ration of the system, a kinetic study of amplification
related to the number of cycles was performed. The
sequence primers were: forward 5'-CATGAAGAGAA-
GACACTGACCATGGAAA-3' and reverse 3'-TGGATA-
GAGGCTAAGTGT AGACACG-5', the product size was
329 pb.
Statistical analysis
Mean and standard deviation were calculated and their
variance evaluated by means of ANOVA test. A difference
was considered significant when P value was less than
0.05. The statistical software used was STAT 32 (SPSS
Inc.).
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